- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06263426
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
HOPE in Action Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes
Study Overview
Detailed Description
Previously, people with HIV in need of a transplant could only receive organs from a donor without HIV. However, in November 2013, the HIV Organ Policy Equity (HOPE) Act made it possible for people with HIV to receive organs from donors with HIV as a part of a research study.
Over the last two decades, people with HIV have received organs from donors without HIV, and in general, these recipients have done well after transplant and still maintained control of their HIV. Over the last several years, people with HIV have received organs from donors with HIV, and in general, these recipients have also done well after transplant and still maintained control of their HIV. This study will look to better understand rejection in transplant recipients with HIV (HIVR+) who receive kidneys from donors with HIV (HIVD+) vs without HIV (HIVD-).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Christine Durand, MD
- Phone Number: 410-614-6702
- Email: cdurand2@jhmi.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
Principal Investigator:
- Shikha Mehta, MD
-
Contact:
- Shikha Mehta, MD
- Email: smehta@uabmc.edu
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
Contact:
- Joanna Schaenman, MD, PhD
- Email: JSchaenman@mednet.ucla.edu
-
Principal Investigator:
- Joanna Schaenman, MD, PhD
-
San Diego, California, United States, 92037
- University of California, San Diego
-
Principal Investigator:
- Saima Aslam, MBBS
-
Contact:
- Saima Aslam, MBBS
- Email: saslam@ucsd.edu
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
Principal Investigator:
- Garrett Roll, MD
-
Contact:
- Garrett Roll, MD
- Email: Garrett.Roll@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale School of Medicine
-
Principal Investigator:
- Maricar Malinis, MD
-
Contact:
- Maricar Malinis, MD
- Email: maricar.malinis@yale.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Contact:
- Carlos Santos, MD
- Email: Carlos_A_Santos@rush.edu
-
Principal Investigator:
- Carlos Santos, MD
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
Contact:
- Jonathan Hand, MD
- Email: jonathan.hand@ochsner.org
-
Principal Investigator:
- Jonathan Hand, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
Principal Investigator:
- Christine Durand, MD
-
Contact:
- Christine Durand, MD
- Email: cdurand2@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Principal Investigator:
- Nahel Elias, MD
-
Contact:
- Nahel Elias, MD
- Email: elias.nahel@mgh.harvard.edu
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
Principal Investigator:
- Marcus Pereira, MD
-
Contact:
- Marcus Pereira, MD
-
New York, New York, United States, 10016
- New York University
-
Principal Investigator:
- Sapna Mehta, MD
-
Contact:
- Sapna Mehta, MD
- Email: Sapna.mehta@nyumc.org
-
New York, New York, United States, 10065
- Weill Cornell Medical Center
-
Contact:
- Catherine Small, MD
- Email: Cbs9003@med.cornell.edu
-
Principal Investigator:
- Catherine Small, MD
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mt. Sinai
-
Principal Investigator:
- Sander Florman, MD
-
Contact:
- Sander Florman, MD
- Email: Sander.florman@mountsinai.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
Principal Investigator:
- Ghady Haidar, MD
-
Contact:
- Ghady Haidar, MD
- Email: haidarg@upmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant meets local criteria for kidney transplant.
- Participant is able to understand and provide informed consent.
- Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA.
- Participant is ≥ 18 years old.
- Cluster of differentiation 4 (CD4+) T-cell count: ≥ 200/μL within 16 weeks of transplant.
- HIV-1 RNA < 50 copies/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements > 200 copies/mL.
- Participant is not suffering from significant wasting (e.g. body mass index <21) thought to be related to HIV disease.
- Participant meets with an independent advocate.
Exclusion Criteria:
- Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of > 1 month, or primary central nervous system (CNS) lymphoma.
- Participant is pregnant or breastfeeding.
- Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HIV D+/R+
People living with HIV who receive kidneys from deceased donors with HIV
|
Receipt of kidney transplant from a deceased donor with HIV.
|
Experimental: HIV D-/R+
People living with HIV who receive kidneys from deceased donors without HIV
|
Receipt of kidney transplant from a deceased donor without HIV.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence of death and allograft rejection.
Time Frame: From date of transplant to end of year 1
|
Proportion of participants who die or have graft rejection
|
From date of transplant to end of year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant survival
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Time to event (death)
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Graft survival
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Time to event (graft loss)
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Type and severity of graft rejection
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Based on Banff scoring criteria (kidney) for T cell- and antibody-mediated rejection (currently Banff 2019)
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Time to first rejection
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Time to event (first rejection)
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Rate of rejection events over time
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Count of rejection events
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Graft function over time measured by eGFR trajectory
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Estimated glomerular filtration rate, calculated centrally based on local testing results
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of HIV viremia post-transplant
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Cumulative incidence of HIV viremia based on local testing
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of new antiretroviral drug resistance and/or X4 tropic virus posttransplant
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Cumulative incidence of new resistance and/or X4 tropic virus based on local testing
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of bacterial, fungal, viral, and other opportunistic infections posttransplant
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Cumulative incidence of infections
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of surgical and vascular transplant complications post-transplant
Time Frame: In the first year post-transplant
|
Cumulative incidence of complications
|
In the first year post-transplant
|
Incidence and causes of chronic kidney disease post-transplant
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Cumulative incidence of chronic kidney disease (eGFR<60 for more than 3 months)
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of post-transplant malignancies
Time Frame: From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Cumulative incidence of malignancies
|
From transplant through end of follow up (at least 1 year, up to 4 years post-transplant)
|
Incidence of de novo donor specific antibody (DSA)
Time Frame: At month 12 post-transplant
|
Based on central testing
|
At month 12 post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christine Durand, MD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB00387066
- U01AI177211 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on HIV D+/R+
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Oshadi Drug AdministrationCompletedCancer | Metastasis | TumorIsrael
-
Oshadi Drug AdministrationCompleted
-
Oshadi Drug AdministrationSuspended
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and Research; University of LeipzigCompleted
-
University of BathRecruitingAgingUnited Kingdom
-
University of British ColumbiaActive, not recruitingHyperglycemia | Diabetes | KetosisCanada
-
Charles Porter, MDMedtronicCompletedHeart Failure; With DecompensationUnited States
-
University of British ColumbiaActive, not recruitingHyperglycemia | Diabetes Mellitus, Type 2 | KetosisCanada